RU2695227C9 - Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция - Google Patents
Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция Download PDFInfo
- Publication number
- RU2695227C9 RU2695227C9 RU2018106904A RU2018106904A RU2695227C9 RU 2695227 C9 RU2695227 C9 RU 2695227C9 RU 2018106904 A RU2018106904 A RU 2018106904A RU 2018106904 A RU2018106904 A RU 2018106904A RU 2695227 C9 RU2695227 C9 RU 2695227C9
- Authority
- RU
- Russia
- Prior art keywords
- mmol
- methyl
- sulfonamide
- alkyl
- stirred
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- UYJSDFHXPYMBBN-UHFFFAOYSA-N 1,3,4-oxadiazole sulfamide Chemical class NS(N)(=O)=O.c1nnco1 UYJSDFHXPYMBBN-UHFFFAOYSA-N 0.000 title claims description 19
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 238
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 201000010099 disease Diseases 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 22
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 21
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 21
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- -1 substituted Chemical class 0.000 claims description 275
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 150000003222 pyridines Chemical class 0.000 claims 3
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 23
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 717
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 677
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 495
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 346
- 239000011541 reaction mixture Substances 0.000 description 301
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 261
- 239000000243 solution Substances 0.000 description 246
- 229920006395 saturated elastomer Polymers 0.000 description 243
- 235000019439 ethyl acetate Nutrition 0.000 description 226
- 239000007787 solid Substances 0.000 description 196
- 238000000605 extraction Methods 0.000 description 191
- 239000012044 organic layer Substances 0.000 description 191
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 189
- 239000007864 aqueous solution Substances 0.000 description 167
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 166
- 229910004298 SiO 2 Inorganic materials 0.000 description 161
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 144
- 239000011780 sodium chloride Substances 0.000 description 131
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 130
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 123
- 238000006243 chemical reaction Methods 0.000 description 123
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 96
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 82
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 74
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- 239000000203 mixture Substances 0.000 description 67
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 66
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 65
- 235000017557 sodium bicarbonate Nutrition 0.000 description 65
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- 230000002829 reductive effect Effects 0.000 description 57
- 239000002904 solvent Substances 0.000 description 57
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 56
- 235000001968 nicotinic acid Nutrition 0.000 description 56
- 239000011664 nicotinic acid Substances 0.000 description 56
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 54
- 238000001914 filtration Methods 0.000 description 53
- 239000002244 precipitate Substances 0.000 description 53
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 49
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- IYXUFOCLMOXQSL-UHFFFAOYSA-N (2,2-difluoroacetyl) 2,2-difluoroacetate Chemical compound FC(F)C(=O)OC(=O)C(F)F IYXUFOCLMOXQSL-UHFFFAOYSA-N 0.000 description 41
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 40
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 38
- 235000019270 ammonium chloride Nutrition 0.000 description 37
- 238000000746 purification Methods 0.000 description 37
- 239000012043 crude product Substances 0.000 description 32
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 108010023925 Histone Deacetylase 6 Proteins 0.000 description 30
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 30
- IBTWUVRCFHJPKN-UHFFFAOYSA-N hydron;pyridine-3-carboxylic acid;chloride Chemical compound Cl.OC(=O)C1=CC=CN=C1 IBTWUVRCFHJPKN-UHFFFAOYSA-N 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 14
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 14
- 235000011054 acetic acid Nutrition 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- RADPVVIPUAGLPO-PHIMTYICSA-N (3r,5s)-3,5-dimethyl-1-phenylpiperazine Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=CC=CC=C1 RADPVVIPUAGLPO-PHIMTYICSA-N 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- DWXLVZSMXXCSMJ-UHFFFAOYSA-N piperazine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCNCC1 DWXLVZSMXXCSMJ-UHFFFAOYSA-N 0.000 description 11
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 10
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 10
- IRQSKJQDKUAART-UHFFFAOYSA-N methyl 6-(bromomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)N=C1 IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- GMMLZJCPYIMGON-UHFFFAOYSA-N N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenylpiperazine-1-sulfonamide hydrochloride Chemical compound Cl.Fc1cc(ccc1CN(c1ccccc1)S(=O)(=O)N1CCNCC1)-c1nnc(o1)C(F)(F)F GMMLZJCPYIMGON-UHFFFAOYSA-N 0.000 description 9
- FKRNPUPIHAVTJL-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-N-phenylpiperazine-1-sulfonamide hydrochloride Chemical compound Cl.FC(F)c1nnc(o1)-c1ccc(CN(c2ccccc2)S(=O)(=O)N2CCNCC2)c(F)c1 FKRNPUPIHAVTJL-UHFFFAOYSA-N 0.000 description 9
- SZTLIGHKSIXTGE-UHFFFAOYSA-N O1CC(C1)N1CCN(CC1)C1=CC=CC=C1 Chemical compound O1CC(C1)N1CCN(CC1)C1=CC=CC=C1 SZTLIGHKSIXTGE-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- GRBUTWWFTFQSMF-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-methylpiperazine Chemical compound C1CNC(C)CN1C1=CC=CC(Cl)=C1 GRBUTWWFTFQSMF-UHFFFAOYSA-N 0.000 description 8
- CXKADMFVIMIQMK-UHFFFAOYSA-N 3-methyl-1-(3-methylphenyl)piperazine Chemical compound C1CNC(C)CN1C1=CC=CC(C)=C1 CXKADMFVIMIQMK-UHFFFAOYSA-N 0.000 description 8
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- 229930040373 Paraformaldehyde Natural products 0.000 description 8
- 229920002866 paraformaldehyde Polymers 0.000 description 8
- NHJFHAQBMGFFPV-UHFFFAOYSA-N 1,1-dioxo-1,4-thiazinane-4-sulfonamide Chemical compound NS(=O)(=O)N1CCS(=O)(=O)CC1 NHJFHAQBMGFFPV-UHFFFAOYSA-N 0.000 description 7
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 7
- 229940124530 sulfonamide Drugs 0.000 description 7
- 230000002194 synthesizing effect Effects 0.000 description 7
- KGXZZTJAKXHMFS-BETUJISGSA-N (2R,6S)-1-ethyl-2,6-dimethyl-4-phenylpiperazine Chemical compound C(C)N1[C@H](CN(C[C@H]1C)C1=CC=CC=C1)C KGXZZTJAKXHMFS-BETUJISGSA-N 0.000 description 6
- VCGNHCJYGWZGMH-UHFFFAOYSA-N 1,2-dimethyl-4-(3-methylphenyl)piperazine Chemical compound CC1CN(CCN1C)C=1C=C(C=CC=1)C VCGNHCJYGWZGMH-UHFFFAOYSA-N 0.000 description 6
- VTVVNBWAQWOSKB-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-4-(oxetan-3-yl)piperazine Chemical compound ClC=1C=C(C=CC=1F)N1CCN(CC1)C1COC1 VTVVNBWAQWOSKB-UHFFFAOYSA-N 0.000 description 6
- UVVZJWAYADASDN-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-4-cyclobutylpiperazine Chemical compound ClC=1C=C(C=CC=1F)N1CCN(CC1)C1CCC1 UVVZJWAYADASDN-UHFFFAOYSA-N 0.000 description 6
- MALBGOTVCYKCHP-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-4-propan-2-ylpiperazine Chemical compound ClC=1C=C(C=CC=1F)N1CCN(CC1)C(C)C MALBGOTVCYKCHP-UHFFFAOYSA-N 0.000 description 6
- XVJGMMIQHDGDBM-TXEJJXNPSA-N 1-[(2R,6S)-2,6-dimethyl-4-phenylpiperazin-1-yl]ethanone Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)C1=CC=CC=C1)C XVJGMMIQHDGDBM-TXEJJXNPSA-N 0.000 description 6
- ILNDDBQCSMETGT-UHFFFAOYSA-N 2-methyl-4-(3-methylphenyl)-1-(oxetan-3-yl)piperazine Chemical compound CC1CN(CCN1C1COC1)C=1C=C(C=CC=1)C ILNDDBQCSMETGT-UHFFFAOYSA-N 0.000 description 6
- PMMFKLZNHANHKY-UHFFFAOYSA-N 4-(3-chlorophenyl)-1,2-dimethylpiperazine Chemical compound ClC=1C=C(C=CC=1)N1CC(N(CC1)C)C PMMFKLZNHANHKY-UHFFFAOYSA-N 0.000 description 6
- ZEZGEMKPVIDDHY-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-1-(oxetan-3-yl)piperazine Chemical compound ClC=1C=C(C=CC=1)N1CC(N(CC1)C1COC1)C ZEZGEMKPVIDDHY-UHFFFAOYSA-N 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 239000012455 biphasic mixture Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- KNBZBXCCUDRUIK-UHFFFAOYSA-N pyridine-3-carboxylic acid;dihydrochloride Chemical compound Cl.Cl.OC(=O)C1=CC=CN=C1 KNBZBXCCUDRUIK-UHFFFAOYSA-N 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 150000001243 acetic acids Chemical class 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 5
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 208000033808 peripheral neuropathy Diseases 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 150000003335 secondary amines Chemical class 0.000 description 5
- DFMBSQZAWARSBI-AOOOYVTPSA-N (3S,5R)-3,5-dimethyl-1-pyridin-3-ylpiperazine Chemical compound C[C@H]1CN(C[C@H](N1)C)C=1C=NC=CC=1 DFMBSQZAWARSBI-AOOOYVTPSA-N 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- BJBOWDALRUFJLC-UHFFFAOYSA-N N-[[2-fluoro-4-(hydrazinecarbonyl)phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=CC(=C1)C(=O)NN BJBOWDALRUFJLC-UHFFFAOYSA-N 0.000 description 4
- ZZYMXJMHXUUOIL-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenyl-2,7-diazaspiro[3.5]nonane-7-sulfonamide hydrochloride Chemical compound Cl.FC(F)c1nnc(o1)-c1ccc(CN(c2ccccc2)S(=O)(=O)N2CCC3(CNC3)CC2)cc1 ZZYMXJMHXUUOIL-UHFFFAOYSA-N 0.000 description 4
- TXDXMESLKFPIPG-UHFFFAOYSA-N N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCN(CC1)C1COC1)C1=CC=CC=C1 TXDXMESLKFPIPG-UHFFFAOYSA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000004572 zinc-binding Effects 0.000 description 4
- WEKGQNRDGWGPTP-PHIMTYICSA-N (2R,6S)-1,2,6-trimethyl-4-pyridin-3-ylpiperazine Chemical compound C[C@H]1CN(C[C@H](N1C)C)C=1C=NC=CC=1 WEKGQNRDGWGPTP-PHIMTYICSA-N 0.000 description 3
- KFYVGMJUWPJVKR-OKILXGFUSA-N (2S,6R)-2,6-dimethyl-4-phenyl-1-propylpiperazine Chemical compound C[C@H]1CN(C[C@H](N1CCC)C)C1=CC=CC=C1 KFYVGMJUWPJVKR-OKILXGFUSA-N 0.000 description 3
- UWFMKHYRFAMSRG-TXEJJXNPSA-N (2r,6s)-1,2,6-trimethyl-4-phenylpiperazine Chemical compound C1[C@@H](C)N(C)[C@@H](C)CN1C1=CC=CC=C1 UWFMKHYRFAMSRG-TXEJJXNPSA-N 0.000 description 3
- PPWCLGXCFRCCNO-CQSZACIVSA-N (3R)-N-(3-chlorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,4-dimethylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@H](N(CC1)C)C)CC1=NC=C(C=C1)C(=O)NN PPWCLGXCFRCCNO-CQSZACIVSA-N 0.000 description 3
- HBPXHBOXPPFFLL-HDICACEKSA-N (3R,5S)-4-ethyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C(=O)NN)C HBPXHBOXPPFFLL-HDICACEKSA-N 0.000 description 3
- PPWCLGXCFRCCNO-AWEZNQCLSA-N (3S)-N-(3-chlorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,4-dimethylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@@H](N(CC1)C)C)CC1=NC=C(C=C1)C(=O)NN PPWCLGXCFRCCNO-AWEZNQCLSA-N 0.000 description 3
- NRNMQRZXSDAUNV-CALCHBBNSA-N (3S,5R)-4-acetyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C(=O)NN)C NRNMQRZXSDAUNV-CALCHBBNSA-N 0.000 description 3
- XANKMFKGBYYKEO-IYBDPMFKSA-N (3S,5R)-4-acetyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=NC=C(C=C1)C(=O)NN)C XANKMFKGBYYKEO-IYBDPMFKSA-N 0.000 description 3
- PGIDISFWNCCCQU-CALCHBBNSA-N (3S,5R)-4-ethyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=NC=C(C=C1)C(=O)NN)C PGIDISFWNCCCQU-CALCHBBNSA-N 0.000 description 3
- GTKRJDLEJFQFSO-CALCHBBNSA-N (3S,5R)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,4,5-trimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)C)C)C2=CC=CC=C2)C=C1 GTKRJDLEJFQFSO-CALCHBBNSA-N 0.000 description 3
- IVSXPSZVWKOGIV-KDURUIRLSA-N (3S,5R)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenyl-4-propylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)CCC)C)C2=CC=CC=C2)C=C1 IVSXPSZVWKOGIV-KDURUIRLSA-N 0.000 description 3
- ZKYIQAJCERVIED-IYBDPMFKSA-N (3S,5R)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N[C@@H](C2)C)C)C2=CC=CC=C2)C=C1 ZKYIQAJCERVIED-IYBDPMFKSA-N 0.000 description 3
- DMOAMYCSRCBVRO-UHFFFAOYSA-N 1-(3-chlorophenyl)-4-cyclobutylpiperazine Chemical compound ClC=1C=C(C=CC=1)N1CCN(CC1)C1CCC1 DMOAMYCSRCBVRO-UHFFFAOYSA-N 0.000 description 3
- FRKOAZXAWJHVIL-PHIMTYICSA-N 1-[(2S,6R)-2,6-dimethyl-4-pyridin-3-ylpiperazin-1-yl]ethanone Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)C=1C=NC=CC=1)C FRKOAZXAWJHVIL-PHIMTYICSA-N 0.000 description 3
- SUBIUPDHPUVLDD-UHFFFAOYSA-N 1-cyclobutyl-4-phenylpiperazine Chemical compound C1CCC1N1CCN(C=2C=CC=CC=2)CC1 SUBIUPDHPUVLDD-UHFFFAOYSA-N 0.000 description 3
- WQDDXVGJRSTLED-UHFFFAOYSA-N 1-methyl-4-phenylpiperazine Chemical compound C1CN(C)CCN1C1=CC=CC=C1 WQDDXVGJRSTLED-UHFFFAOYSA-N 0.000 description 3
- KRNQNTPUHRIZIE-UHFFFAOYSA-N 1-phenyl-4-propan-2-ylpiperazine Chemical compound C1CN(C(C)C)CCN1C1=CC=CC=C1 KRNQNTPUHRIZIE-UHFFFAOYSA-N 0.000 description 3
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
- ADPVULAMOJBHGF-UHFFFAOYSA-N 4-[(N-[2-(4-acetylpiperazin-1-yl)ethyl-methylsulfamoyl]anilino)methyl]benzohydrazide Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)NN)C=C1)CCN1CCN(CC1)C(C)=O ADPVULAMOJBHGF-UHFFFAOYSA-N 0.000 description 3
- SBXSUPAFTJURQE-UHFFFAOYSA-N 4-[(N-[methyl-[2-(4-methylpiperazin-1-yl)ethyl]sulfamoyl]anilino)methyl]benzohydrazide Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)NN)C=C1)CCN1CCN(CC1)C SBXSUPAFTJURQE-UHFFFAOYSA-N 0.000 description 3
- AGOLKFPMNFSBIE-UHFFFAOYSA-N 4-[(N-[methyl-[2-(4-methylsulfonylpiperazin-1-yl)ethyl]sulfamoyl]anilino)methyl]benzohydrazide Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)NN)C=C1)CCN1CCN(CC1)S(=O)(=O)C AGOLKFPMNFSBIE-UHFFFAOYSA-N 0.000 description 3
- LHMLTYHGTLLHLM-UHFFFAOYSA-N 4-[(N-[methyl-[2-[4-(oxetan-3-yl)piperazin-1-yl]ethyl]sulfamoyl]anilino)methyl]benzohydrazide Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)NN)C=C1)CCN1CCN(CC1)C1COC1 LHMLTYHGTLLHLM-UHFFFAOYSA-N 0.000 description 3
- YALRMXKAJOCAOY-UHFFFAOYSA-N 4-cyclobutyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-N-phenylpiperazine-1-sulfonamide Chemical compound C1(CCC1)N1CCN(CC1)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C(=O)NN YALRMXKAJOCAOY-UHFFFAOYSA-N 0.000 description 3
- CQXKCHQUVFFRFJ-UHFFFAOYSA-N 4-imidazol-1-ylsulfonyl-1,4-thiazinane 1,1-dioxide Chemical compound N1(C=NC=C1)S(=O)(=O)N1CCS(CC1)(=O)=O CQXKCHQUVFFRFJ-UHFFFAOYSA-N 0.000 description 3
- OLQHDKQJHKZUNN-UHFFFAOYSA-N 4-phenyl-1,4-thiazinane 1,1-dioxide Chemical compound C1CS(=O)(=O)CCN1C1=CC=CC=C1 OLQHDKQJHKZUNN-UHFFFAOYSA-N 0.000 description 3
- VWXHJCRMAHDCOE-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)N1CCN(CC1)C Chemical compound ClC=1C=C(C=CC=1F)N1CCN(CC1)C VWXHJCRMAHDCOE-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KBTBAVGKRMIBGG-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-1,1-dioxo-1,4-thiazinane-4-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)NS(=O)(=O)N1CCS(CC1)(=O)=O KBTBAVGKRMIBGG-UHFFFAOYSA-N 0.000 description 3
- SCYXOMNNCFFUKR-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-4-methylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C)CC1=CC=C(C=C1)C(=O)NN SCYXOMNNCFFUKR-UHFFFAOYSA-N 0.000 description 3
- WUTBVTKGRISCEY-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C(C)C)CC1=CC=C(C=C1)C(=O)NN WUTBVTKGRISCEY-UHFFFAOYSA-N 0.000 description 3
- BEESKMIESFQATF-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C(C)C)CC1=NC=C(C=C1)C(=O)NN BEESKMIESFQATF-UHFFFAOYSA-N 0.000 description 3
- XOKMXDBQCPAIAD-UHFFFAOYSA-N N-[[2-fluoro-4-[[(2,2,2-trifluoroacetyl)amino]carbamoyl]phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=CC(=C1)C(=O)NNC(C(F)(F)F)=O XOKMXDBQCPAIAD-UHFFFAOYSA-N 0.000 description 3
- MQKGWPGZGHLHIS-UHFFFAOYSA-N N-[[4-(hydrazinecarbonyl)phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=C1 MQKGWPGZGHLHIS-UHFFFAOYSA-N 0.000 description 3
- FFIHKZARVLWSBF-UHFFFAOYSA-N N-[[4-(hydrazinecarbonyl)phenyl]methyl]-N-phenyl-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2CCN(CC2)C(C)C)C2=CC=CC=C2)C=C1 FFIHKZARVLWSBF-UHFFFAOYSA-N 0.000 description 3
- IHINKXGILMAZFH-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-4-methyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C)C2=CC=CC=C2)C=C1)F)F IHINKXGILMAZFH-UHFFFAOYSA-N 0.000 description 3
- AINBCYKSGSHONS-UHFFFAOYSA-N N-[[4-[[(2,2-difluoroacetyl)amino]carbamoyl]-2-fluorophenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C(=O)NNC(=O)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=C1)F)F AINBCYKSGSHONS-UHFFFAOYSA-N 0.000 description 3
- FOPLASVJJVASDO-UHFFFAOYSA-N N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-1,1-dioxo-N-phenyl-1,4-thiazinane-4-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCS(CC1)(=O)=O)C1=CC=CC=C1 FOPLASVJJVASDO-UHFFFAOYSA-N 0.000 description 3
- XDEVYCJFXACEHC-UHFFFAOYSA-N N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-methyl-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCN(CC1)C)C1=CC=CC=C1 XDEVYCJFXACEHC-UHFFFAOYSA-N 0.000 description 3
- KICXPSMHEVWYGF-UHFFFAOYSA-N N-[[5-[[(2,2-difluoroacetyl)amino]carbamoyl]pyridin-2-yl]methyl]-1,1-dioxo-N-phenyl-1,4-thiazinane-4-sulfonamide Chemical compound FC(C(=O)NNC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCS(CC1)(=O)=O)C1=CC=CC=C1)F KICXPSMHEVWYGF-UHFFFAOYSA-N 0.000 description 3
- BNSGQDTZFBNXHD-UHFFFAOYSA-N N-[[5-[[(2,2-difluoroacetyl)amino]carbamoyl]pyridin-2-yl]methyl]-4-methyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C(=O)NNC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCN(CC1)C)C1=CC=CC=C1)F BNSGQDTZFBNXHD-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- MOBCWOUSSISGBJ-UHFFFAOYSA-N methyl 4-(anilinomethyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNC1=CC=CC=C1 MOBCWOUSSISGBJ-UHFFFAOYSA-N 0.000 description 3
- OJBQAHZJVDWSFD-UHFFFAOYSA-N methyl 4-(bromomethyl)-3-fluorobenzoate Chemical compound COC(=O)C1=CC=C(CBr)C(F)=C1 OJBQAHZJVDWSFD-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical group NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 3
- DNYNOAZZKBMKEY-QGZVFWFLSA-N tert-butyl (2R)-4-[(3-chlorophenyl)-[(5-methoxycarbonylpyridin-2-yl)methyl]sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C)CC1=NC=C(C=C1)C(=O)OC DNYNOAZZKBMKEY-QGZVFWFLSA-N 0.000 description 3
- VTFFRINHSSWGGS-GFCCVEGCSA-N tert-butyl (2R)-4-[(3-chlorophenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)NS(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C VTFFRINHSSWGGS-GFCCVEGCSA-N 0.000 description 3
- DBKFFTQNQUMCCG-LJQANCHMSA-N tert-butyl (2R)-4-[(5-methoxycarbonylpyridin-2-yl)methyl-(3-methylphenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound COC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C)C=1C=C(C=CC=1)C DBKFFTQNQUMCCG-LJQANCHMSA-N 0.000 description 3
- AZYSTQVBQRUVBG-LLVKDONJSA-N tert-butyl (2R)-4-imidazol-1-ylsulfonyl-2-methylpiperazine-1-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C AZYSTQVBQRUVBG-LLVKDONJSA-N 0.000 description 3
- JXUODWWRSLAQRB-BGYRXZFFSA-N tert-butyl (2R,6S)-4-[(4-methoxycarbonylphenyl)methyl-phenylsulfamoyl]-2,6-dimethylpiperazine-1-carboxylate Chemical compound COC(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)C(=O)OC(C)(C)C)C)C2=CC=CC=C2)C=C1 JXUODWWRSLAQRB-BGYRXZFFSA-N 0.000 description 3
- CBOTWIPHDYJGCT-KDURUIRLSA-N tert-butyl (2R,6S)-4-[(4-methoxycarbonylphenyl)methyl-pyridin-3-ylsulfamoyl]-2,6-dimethylpiperazine-1-carboxylate Chemical compound COC(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)C(=O)OC(C)(C)C)C)C=2C=NC=CC=2)C=C1 CBOTWIPHDYJGCT-KDURUIRLSA-N 0.000 description 3
- GDHQMKXMTLIWIX-KDURUIRLSA-N tert-butyl (2R,6S)-4-[(5-methoxycarbonylpyridin-2-yl)methyl-phenylsulfamoyl]-2,6-dimethylpiperazine-1-carboxylate Chemical compound COC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@@H](N([C@@H](C1)C)C(=O)OC(C)(C)C)C)C1=CC=CC=C1 GDHQMKXMTLIWIX-KDURUIRLSA-N 0.000 description 3
- DNYNOAZZKBMKEY-KRWDZBQOSA-N tert-butyl (2S)-4-[(3-chlorophenyl)-[(5-methoxycarbonylpyridin-2-yl)methyl]sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C)CC1=NC=C(C=C1)C(=O)OC DNYNOAZZKBMKEY-KRWDZBQOSA-N 0.000 description 3
- VTFFRINHSSWGGS-LBPRGKRZSA-N tert-butyl (2S)-4-[(3-chlorophenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)NS(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C VTFFRINHSSWGGS-LBPRGKRZSA-N 0.000 description 3
- DBKFFTQNQUMCCG-IBGZPJMESA-N tert-butyl (2S)-4-[(5-methoxycarbonylpyridin-2-yl)methyl-(3-methylphenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound COC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C)C=1C=C(C=CC=1)C DBKFFTQNQUMCCG-IBGZPJMESA-N 0.000 description 3
- AZYSTQVBQRUVBG-NSHDSACASA-N tert-butyl (2S)-4-imidazol-1-ylsulfonyl-2-methylpiperazine-1-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C AZYSTQVBQRUVBG-NSHDSACASA-N 0.000 description 3
- OSJGNTQIRSHPHD-TXEJJXNPSA-N tert-butyl (2S,6R)-4-imidazol-1-ylsulfonyl-2,6-dimethylpiperazine-1-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1C[C@@H](N([C@@H](C1)C)C(=O)OC(C)(C)C)C OSJGNTQIRSHPHD-TXEJJXNPSA-N 0.000 description 3
- VRXIOAYUQIITBU-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCO)CC1 VRXIOAYUQIITBU-UHFFFAOYSA-N 0.000 description 3
- CDIHFTFPAMXLPR-UHFFFAOYSA-N tert-butyl 7-(phenylsulfamoyl)-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound C1(=CC=CC=C1)NS(=O)(=O)N1CCC2(CN(C2)C(=O)OC(C)(C)C)CC1 CDIHFTFPAMXLPR-UHFFFAOYSA-N 0.000 description 3
- DHIMTNJVFMCKTP-UHFFFAOYSA-N tert-butyl 7-[(4-methoxycarbonylphenyl)methyl-phenylsulfamoyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound COC(=O)C1=CC=C(CN(S(=O)(=O)N2CCC3(CN(C3)C(=O)OC(C)(C)C)CC2)C2=CC=CC=C2)C=C1 DHIMTNJVFMCKTP-UHFFFAOYSA-N 0.000 description 3
- VTDREWHSMRBXRQ-UHFFFAOYSA-N tert-butyl 7-[[4-(hydrazinecarbonyl)phenyl]methyl-phenylsulfamoyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2CCC3(CN(C3)C(=O)OC(C)(C)C)CC2)C2=CC=CC=C2)C=C1 VTDREWHSMRBXRQ-UHFFFAOYSA-N 0.000 description 3
- BWHAQEBHTQZIRY-UHFFFAOYSA-N tert-butyl 7-imidazol-1-ylsulfonyl-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)OC(C)(C)C)CC1 BWHAQEBHTQZIRY-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- JZHCKADNAOZCKV-CQSZACIVSA-N (3R)-N-(3-chlorophenyl)-N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-3,4-dimethylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@H](N(CC1)C)C)CC1=NC=C(C=C1)C=1OC(=NN=1)C(F)F JZHCKADNAOZCKV-CQSZACIVSA-N 0.000 description 2
- XBVNSJOPOYPPEM-IYBDPMFKSA-N (3R,5S)-4-(2,2-difluoroacetyl)-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F)C)F XBVNSJOPOYPPEM-IYBDPMFKSA-N 0.000 description 2
- MPQLERWNCCSZSP-CALCHBBNSA-N (3R,5S)-N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-4-ethyl-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@@H](N([C@@H](C1)C)CC)C)C1=CC=CC=C1)F MPQLERWNCCSZSP-CALCHBBNSA-N 0.000 description 2
- JZHCKADNAOZCKV-AWEZNQCLSA-N (3S)-N-(3-chlorophenyl)-N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-3,4-dimethylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@@H](N(CC1)C)C)CC1=NC=C(C=C1)C=1OC(=NN=1)C(F)F JZHCKADNAOZCKV-AWEZNQCLSA-N 0.000 description 2
- SIFPUGLXNQJRKW-IYBDPMFKSA-N (3S,5R)-4-acetyl-N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=NC=C(C=C1)C=1OC(=NN=1)C(F)F)C SIFPUGLXNQJRKW-IYBDPMFKSA-N 0.000 description 2
- SHWOZVSIKHTNSB-UHFFFAOYSA-N 1,1-dioxo-N-phenyl-1,4-thiazinane-4-sulfonamide Chemical compound C1(=CC=CC=C1)NS(=O)(=O)N1CCS(CC1)(=O)=O SHWOZVSIKHTNSB-UHFFFAOYSA-N 0.000 description 2
- TUPKOKWZZPSNQQ-UHFFFAOYSA-N 1-(3-chlorophenyl)-4-(oxetan-3-yl)piperazine Chemical compound ClC=1C=C(C=CC=1)N1CCN(CC1)C1COC1 TUPKOKWZZPSNQQ-UHFFFAOYSA-N 0.000 description 2
- VKCBXONEZGIOSP-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonylazetidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC1 VKCBXONEZGIOSP-UHFFFAOYSA-N 0.000 description 2
- USPZDUMJHUANKM-UHFFFAOYSA-N 1-[4-[2-[[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl-phenylsulfamoyl]-methylamino]ethyl]piperazin-1-yl]ethanone Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F)CCN1CCN(CC1)C(C)=O USPZDUMJHUANKM-UHFFFAOYSA-N 0.000 description 2
- ZLKNPIVTWNMMMH-UHFFFAOYSA-N 1-imidazol-1-ylsulfonylimidazole Chemical compound C1=CN=CN1S(=O)(=O)N1C=CN=C1 ZLKNPIVTWNMMMH-UHFFFAOYSA-N 0.000 description 2
- NWWVDTMFZKRSME-UHFFFAOYSA-N 2-cyclobutyl-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenyl-2,7-diazaspiro[3.5]nonane-7-sulfonamide Chemical compound C1(CCC1)N1CC2(C1)CCN(CC2)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F NWWVDTMFZKRSME-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 2
- IRMXWQPVXSDKRJ-UHFFFAOYSA-N 4-acetyl-N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1CCN(CC1)S(=O)(=O)N(C1=CC=CC=C1)CC1=C(C=C(C=C1)C=1OC(=NN=1)C(F)(F)F)F IRMXWQPVXSDKRJ-UHFFFAOYSA-N 0.000 description 2
- KZVFDDQUTOBPRZ-UHFFFAOYSA-N 4-acetyl-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1CCN(CC1)S(=O)(=O)N(C1=CC=CC=C1)CC1=C(C=C(C=C1)C=1OC(=NN=1)C(F)F)F KZVFDDQUTOBPRZ-UHFFFAOYSA-N 0.000 description 2
- UQPZQERGYWSGSR-UHFFFAOYSA-N 4-cyclobutyl-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenylpiperazine-1-sulfonamide Chemical compound C1(CCC1)N1CCN(CC1)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F UQPZQERGYWSGSR-UHFFFAOYSA-N 0.000 description 2
- LFMBBMBMQSXRJM-UHFFFAOYSA-N 4-ethyl-N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)N1CCN(CC1)S(=O)(=O)N(C1=CC=CC=C1)CC1=C(C=C(C=C1)C=1OC(=NN=1)C(F)(F)F)F LFMBBMBMQSXRJM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039869 Histone H2B type F-S Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- XPMZKRDZZWCBDE-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-methylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F XPMZKRDZZWCBDE-UHFFFAOYSA-N 0.000 description 2
- ZLUDPFYCVKEKJM-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C(C)C)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F ZLUDPFYCVKEKJM-UHFFFAOYSA-N 0.000 description 2
- PDWGHKTZSKXPIH-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C(C)C)CC1=NC=C(C=C1)C=1OC(=NN=1)C(F)F PDWGHKTZSKXPIH-UHFFFAOYSA-N 0.000 description 2
- MVKSCNPSFAUQTD-UHFFFAOYSA-N N-(3-chlorophenyl)-4-cyclobutyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1CCN(CC1)C1CCC1)CC1=NC=C(C=C1)C(=O)NN MVKSCNPSFAUQTD-UHFFFAOYSA-N 0.000 description 2
- SKERKVZQZGFZSS-UHFFFAOYSA-N N-(3-fluorophenyl)-N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-methylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C)C2=CC(=CC=C2)F)C=CC(=C1)C=1OC(=NN=1)C(F)(F)F SKERKVZQZGFZSS-UHFFFAOYSA-N 0.000 description 2
- YIMYMZMBPHDTOB-UHFFFAOYSA-N N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-(2-methylpropanoyl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C(C(C)C)=O)C2=CC=CC=C2)C=CC(=C1)C=1OC(=NN=1)C(F)(F)F YIMYMZMBPHDTOB-UHFFFAOYSA-N 0.000 description 2
- STVRPRHLAJSSQQ-UHFFFAOYSA-N N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=CC(=C1)C=1OC(=NN=1)C(F)(F)F STVRPRHLAJSSQQ-UHFFFAOYSA-N 0.000 description 2
- RSBWQRJDIHARHV-UHFFFAOYSA-N N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-methyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C)C2=CC=CC=C2)C=CC(=C1)C=1OC(=NN=1)C(F)(F)F RSBWQRJDIHARHV-UHFFFAOYSA-N 0.000 description 2
- LDFMJPBFTHEUSR-UHFFFAOYSA-N N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-methylsulfonyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)S(=O)(=O)C)C2=CC=CC=C2)C=CC(=C1)C=1OC(=NN=1)C(F)(F)F LDFMJPBFTHEUSR-UHFFFAOYSA-N 0.000 description 2
- KNLBCLIKFPBKPQ-UHFFFAOYSA-N N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenyl-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C(C)C)C2=CC=CC=C2)C=CC(=C1)C=1OC(=NN=1)C(F)(F)F KNLBCLIKFPBKPQ-UHFFFAOYSA-N 0.000 description 2
- QEIVEKWJCSKAMJ-UHFFFAOYSA-N N-[[2-fluoro-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenyl-4-propanoylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C(CC)=O)C2=CC=CC=C2)C=CC(=C1)C=1OC(=NN=1)C(F)(F)F QEIVEKWJCSKAMJ-UHFFFAOYSA-N 0.000 description 2
- PLKNQFMUAVGVMU-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-4-(2-methylpropanoyl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C(C(C)C)=O)C2=CC=CC=C2)C=C1)F)F PLKNQFMUAVGVMU-UHFFFAOYSA-N 0.000 description 2
- PEKYQMGJZIOWPR-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=C1)F)F PEKYQMGJZIOWPR-UHFFFAOYSA-N 0.000 description 2
- ZHFGKNZMFFXOAB-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-4-ethyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)CC)C2=CC=CC=C2)C=C1)F)F ZHFGKNZMFFXOAB-UHFFFAOYSA-N 0.000 description 2
- OSYBUQRDBLHASQ-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-4-methyl-N-phenylpiperazine-1-sulfonamide hydrochloride Chemical compound Cl.CN1CCN(CC1)S(=O)(=O)N(Cc1ccc(cc1F)-c1nnc(o1)C(F)F)c1ccccc1 OSYBUQRDBLHASQ-UHFFFAOYSA-N 0.000 description 2
- FCYYFNJSDXLLIR-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-4-methylsulfonyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)S(=O)(=O)C)C2=CC=CC=C2)C=C1)F)F FCYYFNJSDXLLIR-UHFFFAOYSA-N 0.000 description 2
- XVWLGCIZTWYAEV-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-N-(3-fluorophenyl)-4-methylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C)C2=CC(=CC=C2)F)C=C1)F)F XVWLGCIZTWYAEV-UHFFFAOYSA-N 0.000 description 2
- APCCFMPHZXCYBJ-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-N-phenyl-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C(C)C)C2=CC=CC=C2)C=C1)F)F APCCFMPHZXCYBJ-UHFFFAOYSA-N 0.000 description 2
- SHDRHSLLGSWURU-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-fluorophenyl]methyl]-N-phenyl-4-propanoylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C(CC)=O)C2=CC=CC=C2)C=C1)F)F SHDRHSLLGSWURU-UHFFFAOYSA-N 0.000 description 2
- IGRSBJKSBMNQFY-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-2-(oxetan-3-yl)-N-phenyl-2,7-diazaspiro[3.5]nonane-7-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC=C(CN(S(=O)(=O)N2CCC3(CN(C3)C3COC3)CC2)C2=CC=CC=C2)C=C1)F IGRSBJKSBMNQFY-UHFFFAOYSA-N 0.000 description 2
- WNYVMZOSZOMPAI-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=C1)F WNYVMZOSZOMPAI-UHFFFAOYSA-N 0.000 description 2
- WYDDEFHNMHADMO-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-[methyl-[2-(4-methylpiperazin-1-yl)ethyl]sulfamoyl]aniline Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F)CCN1CCN(CC1)C WYDDEFHNMHADMO-UHFFFAOYSA-N 0.000 description 2
- UDHJWHNBAFNBAR-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-phenyl-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC=C(CN(S(=O)(=O)N2CCN(CC2)C(C)C)C2=CC=CC=C2)C=C1)F UDHJWHNBAFNBAR-UHFFFAOYSA-N 0.000 description 2
- VMJMRSJTVNYKLJ-UHFFFAOYSA-N N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-1,1-dioxo-N-phenyl-1,4-thiazinane-4-sulfonamide Chemical compound FC(C1=NN=C(O1)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCS(CC1)(=O)=O)C1=CC=CC=C1)F VMJMRSJTVNYKLJ-UHFFFAOYSA-N 0.000 description 2
- ZVXQLPNREXWDPB-UHFFFAOYSA-N N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCN(CC1)C1COC1)C1=CC=CC=C1)F ZVXQLPNREXWDPB-UHFFFAOYSA-N 0.000 description 2
- TZZYLOQLBZNTEZ-UHFFFAOYSA-N N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]-4-methyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCN(CC1)C)C1=CC=CC=C1)F TZZYLOQLBZNTEZ-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- XSBOTWUEDYMRKM-UHFFFAOYSA-N tert-butyl 4-(2-methylsulfonyloxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCOS(C)(=O)=O)CC1 XSBOTWUEDYMRKM-UHFFFAOYSA-N 0.000 description 2
- MBTADYPUSOMXMY-UHFFFAOYSA-N tert-butyl 7-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl-phenylsulfamoyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound FC(C1=NN=C(O1)C1=CC=C(CN(S(=O)(=O)N2CCC3(CN(C3)C(=O)OC(C)(C)C)CC2)C2=CC=CC=C2)C=C1)F MBTADYPUSOMXMY-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GMUDVKDHPFXAED-CALCHBBNSA-N (3S,5R)-4-acetyl-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F)C GMUDVKDHPFXAED-CALCHBBNSA-N 0.000 description 1
- MCDAIVIQTVDVHH-CALCHBBNSA-N (3S,5R)-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-3,4,5-trimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)C)C)C2=CC=CC=C2)C=C1)F MCDAIVIQTVDVHH-CALCHBBNSA-N 0.000 description 1
- GNPTWAQNSHKVRV-KDURUIRLSA-N (3S,5R)-N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-3,5-dimethyl-N-phenyl-4-propylpiperazine-1-sulfonamide Chemical compound FC(C1=NN=C(O1)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)CCC)C)C2=CC=CC=C2)C=C1)F GNPTWAQNSHKVRV-KDURUIRLSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- KUSYIGBGHPOWEL-UHFFFAOYSA-N 2-methyl nonaoic acid Chemical compound CCCCCCCC(C)C(O)=O KUSYIGBGHPOWEL-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- RUCVFOIOCBMGFY-UHFFFAOYSA-N 4-(oxetan-3-yl)-N-phenyl-N-[[5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]piperazine-1-sulfonamide Chemical compound O1CC(C1)N1CCN(CC1)S(=O)(=O)N(CC1=NC=C(C=C1)C=1OC(=NN=1)C(F)(F)F)C1=CC=CC=C1 RUCVFOIOCBMGFY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- QBOXDBZSPAEFNL-UHFFFAOYSA-N CC(C)(C)N(CC1)CCN1S(N(CC(C=CC(C(NNC(C(F)(F)F)=O)=O)=C1)=C1F)C1=CC(F)=CC=C1)(=O)=O Chemical compound CC(C)(C)N(CC1)CCN1S(N(CC(C=CC(C(NNC(C(F)(F)F)=O)=O)=C1)=C1F)C1=CC(F)=CC=C1)(=O)=O QBOXDBZSPAEFNL-UHFFFAOYSA-N 0.000 description 1
- GOSPDTSQSOJPSR-UHFFFAOYSA-N CC(C)(C)N(CC1)CCN1S(N(CC(C=CC(C1=NN=C(C(F)(F)F)O1)=C1)=C1F)C1=CC=CN=C1)(=O)=O Chemical compound CC(C)(C)N(CC1)CCN1S(N(CC(C=CC(C1=NN=C(C(F)(F)F)O1)=C1)=C1F)C1=CC=CN=C1)(=O)=O GOSPDTSQSOJPSR-UHFFFAOYSA-N 0.000 description 1
- IBJDMIAFCHZOTJ-UHFFFAOYSA-N CC(C)(C)N(CC1)CCN1S(N(CC(C=CC(C1=NN=C(C(F)F)O1)=C1)=C1F)C1=CC(F)=CC=C1)(=O)=O Chemical compound CC(C)(C)N(CC1)CCN1S(N(CC(C=CC(C1=NN=C(C(F)F)O1)=C1)=C1F)C1=CC(F)=CC=C1)(=O)=O IBJDMIAFCHZOTJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 102000010958 Cortactin Human genes 0.000 description 1
- 108010037663 Cortactin Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- IIBMRSXNBKZXTI-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-4-cyclobutyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C1CCC1)CC1=NC=C(C=C1)C(=O)NN IIBMRSXNBKZXTI-UHFFFAOYSA-N 0.000 description 1
- FIAZVYIQRLPOGX-UHFFFAOYSA-N N-(3-chlorophenyl)-4-cyclobutyl-N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]methyl]piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1CCN(CC1)C1CCC1)CC1=NC=C(C=C1)C=1OC(=NN=1)C(F)F FIAZVYIQRLPOGX-UHFFFAOYSA-N 0.000 description 1
- GDXILYBAPQUGED-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-[methyl-[2-(4-methylsulfonylpiperazin-1-yl)ethyl]sulfamoyl]aniline Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F)CCN1CCN(CC1)S(=O)(=O)C GDXILYBAPQUGED-UHFFFAOYSA-N 0.000 description 1
- USJBGOJTWAOTTB-UHFFFAOYSA-N N-[[4-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-N-[methyl-[2-[4-(oxetan-3-yl)piperazin-1-yl]ethyl]sulfamoyl]aniline Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C=1OC(=NN=1)C(F)F)CCN1CCN(CC1)C1COC1 USJBGOJTWAOTTB-UHFFFAOYSA-N 0.000 description 1
- FUMHCSLIXZRMJU-UHFFFAOYSA-N N-phenylthiomorpholine-4-sulfonamide Chemical compound C1(=CC=CC=C1)NS(=O)(=O)N1CCSCC1 FUMHCSLIXZRMJU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 1
- 101710107444 Polyamine deacetylase HDAC10 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- DATRVIMZZZVHMP-MRVPVSSYSA-N tert-butyl (2r)-2-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-MRVPVSSYSA-N 0.000 description 1
- DATRVIMZZZVHMP-QMMMGPOBSA-N tert-butyl (2s)-2-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-QMMMGPOBSA-N 0.000 description 1
- RBOGBIZGALIITO-DTORHVGOSA-N tert-butyl (2s,6r)-2,6-dimethylpiperazine-1-carboxylate Chemical compound C[C@H]1CNC[C@@H](C)N1C(=O)OC(C)(C)C RBOGBIZGALIITO-DTORHVGOSA-N 0.000 description 1
- HWLNKJXLGQVMJH-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CCNCC2 HWLNKJXLGQVMJH-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- ASRHZFWROABGOC-UHFFFAOYSA-N thiomorpholine-4-sulfonamide Chemical compound NS(=O)(=O)N1CCSCC1 ASRHZFWROABGOC-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150106177 | 2015-07-27 | ||
| KR10-2015-0106177 | 2015-07-27 | ||
| PCT/KR2016/008218 WO2017018805A1 (en) | 2015-07-27 | 2016-07-27 | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2695227C1 RU2695227C1 (ru) | 2019-07-22 |
| RU2695227C9 true RU2695227C9 (ru) | 2020-03-04 |
Family
ID=57885712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018106904A RU2695227C9 (ru) | 2015-07-27 | 2016-07-27 | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10464911B2 (OSRAM) |
| EP (1) | EP3328844B1 (OSRAM) |
| JP (1) | JP6538266B2 (OSRAM) |
| KR (1) | KR101799005B1 (OSRAM) |
| CN (1) | CN107980040B (OSRAM) |
| AU (1) | AU2016299486B2 (OSRAM) |
| BR (1) | BR112017027798B1 (OSRAM) |
| CA (1) | CA2987570C (OSRAM) |
| DK (1) | DK3328844T3 (OSRAM) |
| ES (1) | ES2774510T3 (OSRAM) |
| HR (1) | HRP20200280T1 (OSRAM) |
| HU (1) | HUE048534T2 (OSRAM) |
| MX (1) | MX376585B (OSRAM) |
| MY (1) | MY194018A (OSRAM) |
| NZ (1) | NZ736432A (OSRAM) |
| PH (1) | PH12017501939A1 (OSRAM) |
| PL (1) | PL3328844T3 (OSRAM) |
| PT (1) | PT3328844T (OSRAM) |
| RU (1) | RU2695227C9 (OSRAM) |
| TW (1) | TWI694074B (OSRAM) |
| WO (1) | WO2017018805A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016258188B2 (en) | 2015-05-07 | 2021-08-26 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| KR20180002730A (ko) | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
| NZ739026A (en) | 2015-07-27 | 2019-03-29 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| KR101799005B1 (ko) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
| BR112018002304B1 (pt) | 2015-08-04 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| WO2017065473A1 (en) | 2015-10-12 | 2017-04-20 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| TW201910328A (zh) * | 2017-07-31 | 2019-03-16 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| KR102059027B1 (ko) * | 2018-01-12 | 2019-12-24 | 주식회사 비엔에이치리서치 | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 |
| KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| BR112021020682A2 (pt) | 2019-04-17 | 2021-12-07 | Fund Kertor | Derivados de 1,3,4-oxadiazol como inibidores de histona deacetilase |
| MX2021014315A (es) | 2019-05-31 | 2022-01-04 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de 1,3,4-oxadiazol homoftalimida como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. |
| CA3144985A1 (en) | 2019-06-27 | 2020-12-30 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Hdac6-activated macrophages, compositions, and uses thereof |
| AR120040A1 (es) | 2019-09-27 | 2022-01-26 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| CA3165424A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| KR102537616B1 (ko) * | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2023000625A (es) * | 2020-07-14 | 2023-02-22 | Chong Kun Dang Pharmaceutical Corp | Nuevos compuestos como inhibidor de histona desacetilasa 6, y composicion farmaceutica que los comprende. |
| JP2023537052A (ja) | 2020-08-07 | 2023-08-30 | イタルファルマコ ソシエタ ペル アチオニ | 新規オキサジアゾール系の選択的ｈｄａｃ６阻害剤 |
| CA3211625A1 (en) * | 2021-04-08 | 2022-10-13 | Chang Sik Lee | 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| TW202308619A (zh) | 2021-05-04 | 2023-03-01 | 美商特納亞治療股份有限公司 | 用於治療代謝疾病和hfpef的hdac6抑制劑 |
| TW202412772A (zh) | 2022-07-19 | 2024-04-01 | 義大利商義大利藥品股份有限公司 | 作為選擇性組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生物 |
| EP4568949A1 (en) | 2022-08-08 | 2025-06-18 | Italfarmaco SpA | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
| KR20240035172A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| IL319658A (en) * | 2022-10-14 | 2025-05-01 | Chong Kun Dang Pharmaceutical Corp | Sulfoximine compounds as histone deacetylase 6 inhibitors, and a pharmaceutical composition comprising the same |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293530A1 (en) * | 2006-06-14 | 2007-12-20 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| US20120289495A1 (en) * | 2010-01-13 | 2012-11-15 | Tempero Pharmaceuticals Inc. | Compounds and methods |
| RU2515611C2 (ru) * | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CA2462601A1 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| IL162498A0 (en) | 2001-12-20 | 2005-11-20 | Bristol Myers Squibb Co | (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same |
| AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP2388263A1 (en) | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
| WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| NZ571271A (en) | 2006-03-23 | 2011-10-28 | Biota Europe Ltd | The use of benzamide or pyridinamide derivatives as antibacterial agents |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| RU2482877C2 (ru) | 2006-12-11 | 2013-05-27 | Дженентек, Инк. | Композиции и способы для лечения опухоли |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| JP2011502133A (ja) | 2007-11-02 | 2011-01-20 | メシルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| SG185925A1 (en) | 2007-11-02 | 2012-12-28 | Momenta Pharmaceuticals Inc | Non-anticoagulant polysaccharide compositions |
| CN102802623A (zh) | 2009-04-20 | 2012-11-28 | 人类健康研究所 | 含有1，3，4-恶二唑衍生物的化合物、组合物和方法 |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| WO2011011186A2 (en) | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
| EP2539327A1 (en) | 2010-02-25 | 2013-01-02 | Piramal Enterprises Limited | Oxadiazole compounds, their preparation and use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| RU2601550C2 (ru) | 2010-12-09 | 2016-11-10 | Вокхардт Лимитед | Кетолидные соединения |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| EP2729454B1 (en) | 2011-07-08 | 2015-09-16 | Novartis AG | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| JP6169076B2 (ja) | 2011-07-20 | 2017-07-26 | ザ ジェネラル ホスピタル コーポレイション | 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤 |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| US9499479B2 (en) | 2011-10-03 | 2016-11-22 | The Trustees Of Columbia University In The City Of New York | Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| BR112014012815A8 (pt) | 2011-11-28 | 2017-06-20 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
| US9345905B2 (en) | 2011-11-29 | 2016-05-24 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents |
| CA2866707A1 (en) | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| CU24345B1 (es) | 2013-09-06 | 2018-05-08 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores |
| DK3080125T3 (en) * | 2013-12-12 | 2019-01-07 | Chong Kun Dang Pharmaceutical Corp | PRESENT UNKNOWN AZA DERIVATIVE DERIVATIVES AS SELECTIVE HISTONDEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THESE |
| CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| ES2713700T3 (es) * | 2014-11-24 | 2019-05-23 | Medifron Dbt Inc | Derivados de carboxamida y urea a base de oxazol y tiazol sustituidos como ligandos del receptor de vainilloide II |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| NZ739026A (en) | 2015-07-27 | 2019-03-29 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| KR101799005B1 (ko) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
| BR112018002304B1 (pt) | 2015-08-04 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| WO2017065473A1 (en) | 2015-10-12 | 2017-04-20 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
-
2016
- 2016-07-27 KR KR1020160095326A patent/KR101799005B1/ko active Active
- 2016-07-27 RU RU2018106904A patent/RU2695227C9/ru active
- 2016-07-27 CA CA2987570A patent/CA2987570C/en active Active
- 2016-07-27 MX MX2017017090A patent/MX376585B/es active IP Right Grant
- 2016-07-27 DK DK16830838.5T patent/DK3328844T3/da active
- 2016-07-27 BR BR112017027798-0A patent/BR112017027798B1/pt active IP Right Grant
- 2016-07-27 EP EP16830838.5A patent/EP3328844B1/en active Active
- 2016-07-27 HU HUE16830838A patent/HUE048534T2/hu unknown
- 2016-07-27 NZ NZ736432A patent/NZ736432A/en unknown
- 2016-07-27 PT PT168308385T patent/PT3328844T/pt unknown
- 2016-07-27 US US15/747,850 patent/US10464911B2/en active Active
- 2016-07-27 MY MYPI2017703935A patent/MY194018A/en unknown
- 2016-07-27 WO PCT/KR2016/008218 patent/WO2017018805A1/en not_active Ceased
- 2016-07-27 TW TW105123853A patent/TWI694074B/zh active
- 2016-07-27 PL PL16830838T patent/PL3328844T3/pl unknown
- 2016-07-27 CN CN201680025249.5A patent/CN107980040B/zh active Active
- 2016-07-27 JP JP2018504096A patent/JP6538266B2/ja active Active
- 2016-07-27 HR HRP20200280TT patent/HRP20200280T1/hr unknown
- 2016-07-27 AU AU2016299486A patent/AU2016299486B2/en active Active
- 2016-07-27 ES ES16830838T patent/ES2774510T3/es active Active
-
2017
- 2017-10-24 PH PH12017501939A patent/PH12017501939A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293530A1 (en) * | 2006-06-14 | 2007-12-20 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| RU2515611C2 (ru) * | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
| US20120289495A1 (en) * | 2010-01-13 | 2012-11-15 | Tempero Pharmaceuticals Inc. | Compounds and methods |
Non-Patent Citations (3)
| Title |
|---|
| Manku S. et al. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors, Bioorganic & Medicinal Chemistry Letters, 19, 7, стр. 1866-1870, 2009. * |
| Manku S. et al. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors, Bioorganic & Medicinal Chemistry Letters, 19, 7, стр. 1866-1870, 2009. Pal, Dilipkumar, Hydroxamic acid - A novel molecule for anticancer therapy, Journal of Advanced Pharmaceutical Technology & Research, 3, 2, стр. 92-99, 2012. * |
| Pal, Dilipkumar, Hydroxamic acid - A novel molecule for anticancer therapy, Journal of Advanced Pharmaceutical Technology & Research, 3, 2, стр. 92-99, 2012. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2695227C9 (ru) | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| US10584117B2 (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
| US10538498B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2709207C2 (ru) | 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их | |
| US10287255B2 (en) | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| JP7428833B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物 | |
| JP7642859B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールチオカルボニル化合物およびこれを含む薬剤学的組成物 | |
| US12466827B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| CN115427406B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| RU2810081C1 (ru) | Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| CA3174319C (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2822624C1 (ru) | Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| KR20250033306A (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 트리아졸 화합물 및 이를 포함하는 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification |